#Cambridge #Brazil #ALS #NeuroSense #PrimeC

NeuroSense Expands Its Patent Portfolio in Brazil

NeuroSense Therapeutics Ltd., a biotechnology company focused on developing innovative treatments for neurodegenerative diseases, recently achieved a significant milestone by securing a Brazilian patent for its proprietary drug composition known as PrimeC. This patent, numbered BR 112024007727-6, was granted by the Brazilian Patent and Trademark Office and is set to protect NeuroSense's intellectual property regarding PrimeC until October 2042, enhancing its global reach.

Significance of the Patent

This new patent is not merely a formality; it represents a critical extension of NeuroSense's previously obtained patents in the United States and Australia. By securing this Brazilian patent, NeuroSense is taking significant steps in fortifying its international intellectual property portfolio. According to Alon Ben-Noon, CEO of NeuroSense, this approval is pivotal as it indicates the durability of their intellectual property strategy regarding PrimeC.

What is PrimeC?

PrimeC is a groundbreaking oral therapy formulated as a fixed-dose combination of two FDA-approved medications, ciprofloxacin and celecoxib. This drug aims to deliver both components in a synchronized, extended-release manner, ensuring that patients receive a consistent therapeutic effect across various pathways involved in neurodegeneration, particularly in diseases like amyotrophic lateral sclerosis (ALS) and Alzheimer's.

The formulation of PrimeC specifically targets mechanisms involved in neuroinflammation, iron dysregulation, and microRNA dysregulation, making it a unique offering in the market. The complex architecture of neurodegenerative diseases necessitates novel therapeutic approaches such as PrimeC, which aims to tackle these issues through a multi-target strategy. NeuroSense plans to initiate Phase 3 clinical trials for PrimeC in ALS shortly, following successful results from earlier trials.

Future Outlook

The potential commercialization of PrimeC hinges on the success of its pivotal trial, dubbed the PARAGON study. Positive results from the earlier Phase 2b PARADIGM trial have set a propitious stage for this next phase, which holds promise for the treatment landscape of ALS—a condition that remains largely untreatable.

With ALS affecting around 5,000 new individuals annually in the U.S. and the disease burden escalating, PrimeC aims to fulfill a significant unmet medical need. Alzheimer’s disease, another critical area of focus, impacts over 30 million people worldwide, and there is an urgent demand for effective treatments that can modify disease progression.

NeuroSense’s strategic focus aligns with this need, as the company envisions developing therapies that address the multifaceted nature of neurodegenerative diseases. This aligns with their overarching mission to enhance the quality of life for patients plagued by such conditions, offering hope where few options currently exist.

NeuroSense Therapeutics is not just another player in the biotechnology arena; it actively engages in seeking innovative solutions that can effectively confront the complexities of neurodegenerative conditions. By reinforcing its intellectual property through strategic patents like the one recently awarded in Brazil, the company strengthens its foundation for future clinical developments and patient benefits.

For more insights and updates, follow NeuroSense on its official channels or visit its website. As the landscape of neurodegenerative treatments evolves, NeuroSense is poised to be at the forefront, paving the way for potentially life-altering therapies.